You have full text access to this OnlineOpen article

Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine

  1. S. MANOLAKOPOULOS1,
  2. S. BETHANIS1,
  3. S. KOUTSOUNAS2,
  4. J. GOULIS3,
  5. J. VLACHOGIANNAKOS4,
  6. E. CHRISTIAS5,
  7. A. SAVERIADIS4,
  8. C. PAVLIDIS2,
  9. C. TRIANTOS1,
  10. A. CHRISTIDOU1,
  11. G. PAPATHEODORIDIS5,
  12. D. KARAMANOLIS4,
  13. D. TZOURMAKLIOTIS1

Article first published online: 6 NOV 2007

DOI: 10.1111/j.1365-2036.2007.03567.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 27, Issue 3, pages 266–273, February 2008

Additional Information

How to Cite

MANOLAKOPOULOS, S., BETHANIS, S., KOUTSOUNAS, S., GOULIS, J., VLACHOGIANNAKOS, J., CHRISTIAS, E., SAVERIADIS, A., PAVLIDIS, C., TRIANTOS, C., CHRISTIDOU, A., PAPATHEODORIDIS, G., KARAMANOLIS, D. and TZOURMAKLIOTIS, D. (2008), Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Alimentary Pharmacology & Therapeutics, 27: 266–273. doi: 10.1111/j.1365-2036.2007.03567.x

Author Information

  1. 1

    Department of Gastroenterology, Polyclinic General Hospital, Athens

  2. 2

    2nd Department of Internal Medicine at General Hospital of IKA, Athens

  3. 3

    4th Academic Department of Internal Medicine at Hippokration Hospital of Thessaloniki, Thessaloniki

  4. 4

    2nd Department of Gastroenterology, Evangelismos General Hospital, Athens

  5. 5

    Department of Medicine, Athens University Medical School, Athens, Greece

*Dr S. Manolakopoulos, 3 Vironos Street, 153 43, Agia Paraskevi, Athens, Greece. E-mail: spilios1@otenet.gr, smanolak@med.uoa.gr

Publication History

  1. Issue published online: 6 NOV 2007
  2. Article first published online: 6 NOV 2007
  3. Publication data Submitted 2 August 2007First decision 3 September 2007 Resubmitted 1 October 2007 Accepted 30 October 2007
Corrected by:

Corrigenda

Vol. 27, Issue 6, 528–529, Article first published online: 20 FEB 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (158K)

References

  • 1
    Lok AS, McMahon B. Chronic hepatitis B. Hepatology 2007; 45: 507–39.
    Direct Link:
  • 2
    Funk ML, Rosemberg DM, Lok AS. World-wide epidemiology of HBeg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 52–61.
    Direct Link:
  • 3
    Ballard AL, Boxall EH. Epidemiology of precore mutants of hepatitis B in the United Kingdom. J Med Virol 2000; 62: 463–70.
    Direct Link:
  • 4
    Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 7–36.
  • 5
    Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617–24.
    Direct Link:
  • 6
    Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. Aliment Pharmacol Ther 2004; 19: 25–37.
    Direct Link:
  • 7
    Gish RG, Perrillo RP, Jacobson IM. Customizing the management of chronic hepatitis B virus infection. Semin Liver Dis 2007; 27 (Suppl. 1): 9–17.
  • 8
    Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2004; 99: 57–63.
    Direct Link:
  • 9
    Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of patients with HBeAg-negative chronic hepatitis B under nucleos(t)ide analogues maintenance therapy starting with lamivudine. Hepatology 2005; 42: 121–9.
    Direct Link:
  • 10
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743–51.
  • 11
    Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937–43.
  • 12
    Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419–27.
  • 13
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90.
  • 14
    Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101.
  • 15
    Kessler HH, Pierer K, Dragon E, et al. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin Diagn Virol 1998; 9: 37–43.
  • 16
    Manolakopoulos S, Bethanis S, Elefsiniotis J, et al. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther 2006; 23: 787–95.
    Direct Link:
  • 17
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–9.
  • 18
    Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219–26.
    Direct Link:
  • 19
    Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching to adefovir therapy in lamivudine resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307–13.
    Direct Link:
  • 20
    Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006; 44: 693A–4A.
  • 21
    Lee YS, Suh D, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385–91.
    Direct Link:
  • 22
    Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2006; 42: 1414–9.
    Direct Link:
  • 23
    Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292–7.
  • 24
    Villeneue JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085–9.
  • 25
    Locarnini S, Qi W, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B (abstract). J Hepatol 2005; 42: 17.
View Full Article (HTML) Get PDF (158K)